News

REACH Incubator Project - First Open Call for Startups and SMEs - webinar on 26.01

Published on | 5 years ago

Programmes
ICT SME Instrument

The European Commission funded the H2020 project project "REACH" (EuRopEAn incubator for trusted and secure data value Chains). REACH will support selected data-fuelled start-ups & SMEs through a 11-month incubation programme facilitating the development of trusted and secure innovative solutions based on industrial and personal data. 

Specifications:

  • Single applicants only.
  • Funding: up to 120000€ in equity free funding
  • Your legal business must be based in a European Member State, Associated Country and be eligible for Horizon 2020 programmes.

Applying can be done by clicking here - deadline February 15th, 2021 at 12:00 (noon) CET

When applying, please inform NCP advisor Magali.parent@vlaio.be.

A webinar about the application process and what you can expect from the incubation programme will be organized on January 26th, 13:00 CET. All details and registration can be found here.

 

 

 

 

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1882 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.